Roche

US agency to rule on Tecentriq’s most important use
US agency to rule on Tecentriq’s most important use
EP Vantage
Roche
Tecentriq
non-squamous non-small cell lung cancer
FDA
Flag link:
Roche's Xolair, challenged in asthma, wins 'breakthrough' in food allergies
Roche's Xolair, challenged in asthma, wins 'breakthrough' in food allergies
Fierce Pharma
Novartis
Roche
Xolair
FDA
food allergies
Flag link:
Drug firms fight US government’s Iraq corruption probe
Drug firms fight US government’s Iraq corruption probe
Pharmaforum
Iraq
DOJ
AstraZeneca
Roche
JNJ
GE
Pfizer
Flag link:
Roche is on the “SurePath” for Cervical Cancer Screening with Approval
Roche is on the “SurePath” for Cervical Cancer Screening with Approval
Medical Devices and Diagnostics Industry
Roche
FDA
HPV
SurePath
diagnostics
Flag link:
Roche gets some regulatory love for its breakthrough quest on a PhIII Huntington’s drug
Roche gets some regulatory love for its breakthrough quest on a PhIII Huntington’s drug
Endpoints
Roche
EMA
Europe
RG6042
IONIS-HTTRx
Huntington's disease
Flag link:
Pfizer Receives European Approval for Herceptin Biosimilar, Trazimera
Pfizer Receives European Approval for Herceptin Biosimilar, Trazimera
CP Wire
Ttrazimera
Pfizer
biosimilars
Herceptin
Europe
Roche
Flag link:
On top of expiring Herceptin patents, Roche faces huge royalty losses in 2019
On top of expiring Herceptin patents, Roche faces huge royalty losses in 2019
Endpoints
Roche
patents
Herceptin
Cabilly patents
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
CP Wire
PureTech
Roche
drug development
antisense
Flag link:
Roche has taken the Trump pledge, joining Pfizer, Novartis and Merck in promising to hold the line on drug prices
Roche has taken the Trump pledge, joining Pfizer, Novartis and Merck in promising to hold the line on drug prices
Endpoints
Roche
Merck
Pfizer
Novartis
drug pricing
Donald Trump
Flag link:
Is Roche's latest Tecentriq win really a win for Merck's Keytruda?
Is Roche's latest Tecentriq win really a win for Merck's Keytruda?
Fierce Pharma
Roche
immuno-oncology
Tecentriw
Merck
Keytruda
non-small cell lung cancer
Flag link:
Roche’s antiviral hits flu targets in PhIII trial
Roche’s antiviral hits flu targets in PhIII trial
Pharma Times
Roche
baloxavir marboxil
antivirals
Flu
Shionogi
Flag link:
Many Drugmakers Ignore Trump—and Raise Prices Anyway
Many Drugmakers Ignore Trump—and Raise Prices Anyway
Bloomberg
drug pricing
Donald Trump
Pfizer
Celgene
Roche
Novo Nordisk
Flag link:
Pharmas call off price hikes after California law forces new warnings: report
Pharmas call off price hikes after California law forces new warnings: report
Fierce Pharma
drug pricing
California
Novo Nordisk
Roche
Novartis
Gilead Sciences
Flag link:
3 Best Biotech Acquisitions of 2018 (So Far)
3 Best Biotech Acquisitions of 2018 (So Far)
Motley Fool
M&A
biotech
Celgene
Juno Therapeutics
Novartis
AveXis
Roche
Foundation Medicine
Flag link:
FDA Limits the Use of Tecentriq and Keytruda
FDA Limits the Use of Tecentriq and Keytruda
RAPS.org
FDA
Roche
Merck
Tecentriq
Keytruda
metastatic urothelial cancer
Flag link:
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Endpoints
Roche
Tecentriq
Genentech
triple negative breast cancer
Celgene
Abraxane
Flag link:
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
Fierce Pharma
Roche
Shionogi
Xofluza
Flu
FDA
Flag link:
With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche?
With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche?
Fierce Pharma
Roche
Tecentriq
clinical trials
small cell lung cancer
Flag link:
Tesaro stock rockets as rumours of Roche takeover abound
Tesaro stock rockets as rumours of Roche takeover abound
Pharmaforum
Tesaro
Roche
M&A
Flag link:

Pages